BRCA2 Mutation (somatic) is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain BRCA2 Mutation (somatic) and breast carcinoma as inclusion criteria, 3 are phase 2 (3 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA2 Mutation (somatic) and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) and 1 is phase 3 (0 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 2 clinical trials for fallopian tube carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 Mutation (somatic) and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 Mutation (somatic) and malignant solid tumor as inclusion criteria, 2 are phase 2 (2 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 2 clinical trials for primary peritoneal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA2 Mutation (somatic) and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 3 (0 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and cancer as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and prostate carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA2 Mutation (somatic) is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 Mutation (somatic) and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].